1. Disease Information

Overview. Progressive Myoclonic Epilepsy Type 7 (EPM7) is a rare autosomal dominant neurologic channelopathy caused by heterozygous variants in KCNC1, the gene encoding the voltage-gated potassium channel subunit Kv3.1. The classic, most extensively characterized phenotype is Myoclonus Epilepsy and Ataxia due to Potassium (K⁺) channel mutation (MEAK), defined by childhood/adolescent-onset progressive action myoclonus that becomes severely disabling, infrequent generalized tonic-clonic seizures, and progressive ataxia. KCNC1 variants are now recognized to cause a broader phenotypic spectrum, collectively termed KCNC1-related disorders, ranging from MEAK/EPM7 at the severe-progressive end, through infantile-onset drug-resistant developmental and epileptic encephalopathy (DEE), to isolated non-progressive myoclonus or intellectual disability without seizures at the mild end (GeneReviews, NBK619809).

Key identifiers: - OMIM phenotype: #616187 — "EPILEPSY, PROGRESSIVE MYOCLONIC 7; EPM7" (OMIM) - OMIM gene: 176258 — "POTASSIUM CHANNEL, VOLTAGE-GATED, SHAW-RELATED SUBFAMILY, MEMBER 1; KCNC1" (OMIM) - Orphanet: ORPHA:435438 — "Progressive myoclonic epilepsy type 7" (Orphanet) - MONDO: MONDO:0014521 - Gene: HGNC:6233 (KCNC1), chromosome 11p15.1 (per GeneCards/OMIM; some sources list 11p15) - MedGen:* C4015420

Synonyms: EPM7; Myoclonic epilepsy and ataxia due to potassium (K⁺) channel mutation (MEAK); Myoclonus epilepsy and ataxia due to KCNC1 mutation; KCNC1-related progressive myoclonus epilepsy; KCNC1-related developmental and epileptic encephalopathy (for the infantile-onset end of the spectrum). Gene aliases: KV3.1, KV4, NGK2.

Evidence basis. Knowledge of this disease derives almost entirely from aggregated case series and case reports in the medical literature (exome-sequencing cohorts of progressive myoclonus epilepsy of unknown cause, GeneReviews summaries, individual/familial case reports), supplemented by functional/electrophysiological studies (heterologous expression in Xenopus oocytes and mammalian cell lines) and mouse models. There is no large population-based EHR resource for this ultra-rare disease; GeneReviews estimates "approximately 60 individuals with a KCNC1-related disorder have been reported in the literature to date."

2. Etiology

Disease causal factor — purely genetic. EPM7/MEAK is caused by heterozygous, almost always de novo, pathogenic variants in KCNC1 (OMIM 616187; GeneReviews NBK619809). There is no known infectious, autoimmune, or acquired cause; this is a monogenic channelopathy.

Genetic risk factors: - The recurrent missense variant c.959G>A (p.Arg320His) in the S4 voltage-sensor segment of Kv3.1 is by far the most common cause of MEAK. It was identified in 13/84 (≈13% of the exome-sequenced cohort, plus additional cases from a secondary cohort) individuals with progressive myoclonus epilepsy of unknown etiology in the landmark discovery study (Muona et al., Nat Genet 2015; PMID: 25401298). Functional studies in Xenopus oocytes showed the mutant channel produced "significantly smaller potassium currents" than wild type, and when co-expressed with wild-type subunits produced a dominant-negative loss-of-function effect, with current amplitude reduced roughly fourfold — consistent with Kv3 channels' obligate tetrameric assembly (one mutant subunit poisons the whole channel). - Additional pathogenic/likely pathogenic variants causing the broader spectrum: p.Ala421Val (recurrent, DEE), p.Cys208Tyr, p.Thr399Met, p.Arg317His, p.Arg339 (nonsense), p.Gln492 (Oliver et al. Ann Neurol 2017, PMID: 31353855 [note: this PMID corresponds to the "Encephalopathies with KCNC1 variants" genotype-phenotype-functional-correlation paper]; Muona et al., PMID: 31353862). - No population allele frequency — the R320H variant and other pathogenic KCNC1 variants are essentially absent from population reference databases (gnomAD), consistent with de novo occurrence and severe phenotype. - Parental (germline/somatic) mosaicism has been documented as a rare but clinically important risk modifier: a case report describes two affected brothers with classic MEAK (near-normal early development, myoclonus onset ~age 10, infrequent generalized seizures, mild cognitive decline) born to an asymptomatic mother carrying the p.Arg320His variant in mosaic form (Yano et al., Brain Dev 2018; PMID: 29428275). This raises recurrence risk in future pregnancies above the background de novo rate despite an unaffected parent.

Environmental risk factors: None established. This is a pure Mendelian channelopathy; there is no evidence for toxin, infectious, or lifestyle contribution to disease initiation.

Protective factors: None specifically described for KCNC1/EPM7 in the literature reviewed.

Gene-environment interactions: Not applicable/not reported — no GxE data exist for this monogenic disorder. (Photic stimulation is a seizure/myoclonus trigger via EEG photosensitivity, discussed under Phenotypes, but this is a symptom-provocation phenomenon rather than a disease-causing environmental factor.)

3. Phenotypes

Classic MEAK/EPM7 phenotype (the "progressive" severe form)

Onset and course: Myoclonus typically begins age 6–14 years (mean ~10 years); generalized seizures usually emerge in adolescence and can continue into the third or fourth decade; ataxia is progressive and, per Orphanet, "generally becomes disabling in adolescence, with most patients becoming wheelchair-bound." GeneReviews states approximately half of affected individuals require a walking aid or wheelchair by late adolescence/early adulthood. Cognitive impairment is not a prominent early feature — early development is typically near-normal — but mild decline can occur after seizure onset in roughly half of patients. Dementia has not been reported.

Developmental and Epileptic Encephalopathy (DEE) phenotype (the infantile-onset severe end)

Associated recurrently with p.Ala421Val: infantile-onset (typically <10 months of age), drug-resistant epilepsy with multiple seizure types (myoclonic, absence, generalized tonic-clonic), moderate-to-severe global developmental delay/intellectual disability (100%) without regression, non-progressive ataxia (~75%), myoclonus in about a third of cases, and feeding difficulties/failure to thrive. Suggested HPO: HP:0200134 (Infantile spasm, if applicable), HP:0011097 (Epileptic spasm), HP:0001263 (Global developmental delay), HP:0001508 (Failure to thrive), HP:0011968 (Feeding difficulties).

Milder end of spectrum

• Isolated non-progressive myoclonus (p.Cys208Tyr)
• Intellectual disability without seizures or epilepsy, associated with the nonsense variant p.Arg339, which acts via nonsense-mediated decay/haploinsufficiency rather than dominant-negative mechanism. Affected individuals across three generations of one family showed delayed motor milestones, speech delay, ID with attention difficulties, hypotonia, and dysmorphic features (epicanthal folds, ptosis, short philtrum, prognathism), with notable absence of seizures* (Muona/Oliver group, PMC5437909). Suggested HPO: HP:0001256 (Intellectual disability, mild), HP:0001252 (Hypotonia).
• Developmental encephalopathy without seizures (p.Arg317His, p.Gln492*)
• Autism spectrum features reported in some individuals.

Quality-of-life impact: No disease-specific EQ-5D/SF-36 data were identified in this search, but the natural-history literature (GeneReviews, case reports) documents major functional impact from progressive ataxia/wheelchair dependence and disabling myoclonus interfering with voluntary movement, feeding, and independence, particularly in adolescence/early adulthood for MEAK and from infancy for DEE.

4. Genetic/Molecular Information

Causal gene: KCNC1 (HGNC:6233; OMIM 176258), encoding Kv3.1*, a member of the Shaw-related (Kv3) subfamily of voltage-gated, tetrameric potassium channels. Chromosome 11p15.1.

Variant classes and functional consequences:

Functional analyses in the KCNC1-related-disorders discovery papers concluded broadly: "Functional analyses demonstrated no measurable currents for all identified variants" in heterologous expression, with dominant-negative activity specifically demonstrated for p.Thr399Met and p.Ala421Val in at least one study, predicting neuronal disinhibition as the shared downstream mechanism (PMID: 31353862).

Zygosity/inheritance: Heterozygous, autosomal dominant. Predominantly de novo (>95% of tested probands per GeneReviews); rare instances of inheritance from a mosaic or subtly-affected parent are documented (PMID: 29428275).

Population frequency: Not present in gnomAD/population databases (consistent with de novo severe disease). GeneReviews estimates the MEAK-causing c.959G>A allele arises at a rate corresponding to roughly 1 per 5,700,000 conceptions.

Epigenetics/chromosomal abnormalities: No epigenetic mechanism (DNA methylation, histone modification) or large chromosomal rearrangement has been reported as causal for EPM7; this is a single-gene, sequence-level channelopathy.

Modifier genes: None specifically established; phenotypic variability is attributed primarily to which KCNC1 variant is present (genotype-phenotype correlation) rather than to a distinct modifier locus.

Suggested ontology terms: HGNC:6233 (KCNC1); GO:0005249 (voltage-gated potassium channel activity, suggested — verify); GO:0071805 (potassium ion transmembrane transport, suggested — verify); GO:0001508 (regulation of action potential, suggested — verify).

5. Environmental Information

No environmental factors (toxins, radiation, occupational exposures), lifestyle factors, or infectious agents have been implicated in causing EPM7/KCNC1-related disorders — this is consistent with its status as a highly penetrant monogenic de novo channelopathy. The one environmentally-modulated clinical phenomenon is photosensitivity: EEG in KCNC1-related PME frequently shows a photoparoxysmal response, i.e., photic stimulation can provoke epileptiform discharges/myoclonus in susceptible patients, which is a clinical trigger relevant to seizure/myoclonus precipitation rather than a cause of the underlying disease.

6. Mechanism / Pathophysiology

Molecular pathway / protein function. Kv3.1 is a member of the Kv3 (Shaw-related) subfamily of voltage-gated K⁺ channels (KCNC1–4, giving Kv3.1–3.4), distinguished biophysically by depolarized voltage-dependence of activation and very rapid activation/deactivation kinetics. This biophysical profile is what permits high-frequency, sustained action potential firing in specific neuron populations. Kv3.1/Kv3.2 are the dominant Kv3 subunits in parvalbumin-positive (PV+) fast-spiking GABAergic interneurons of the cerebral cortex, and Kv3.1/Kv3.3 are highly expressed in cerebellar granule cells and Purkinje cells, where they support rapid repolarization needed for high-frequency spiking and reliable, rapid GABAergic inhibitory neurotransmission.

Causal chain (loss-of-function variants, e.g., p.Arg320His): 1. Trigger: heterozygous de novo missense variant in the KCNC1 S4 voltage sensor (or pore-adjacent regions for other variants). 2. Molecular consequence: because Kv3 channels are obligate homo/heterotetramers, one mutant subunit poisons the channel complex, producing a dominant-negative loss of potassium current far in excess of the 50% predicted by simple haploinsufficiency — up to ~4-fold reduction for R320H. 3. Cellular consequence: PV+ fast-spiking interneurons and Kv3.1-dependent cerebellar granule/Purkinje neurons lose their capacity to sustain high-frequency firing ("cells expressing R320H were unable to support high-frequency firing," Carpenter et al., Epilepsia 2021; PMID: 33735526). 4. Developmental/structural consequence — "developmental dendritopathy": In primary mouse cortical interneuron culture, expressing R320H Kv3.1 "severely impair[ed] neurite development and interneuron viability" — 85.7% of mutant-expressing neurons had undetectable neuronal processes by 7 days in vitro (vs. ~28–31% in controls), with reduced total dendritic length, impaired dendritic arborization, and increased markers of apoptotic cell death (TUNEL-positivity by 72h, proapoptotic nuclear changes by 48h). Notably, this dendritic/viability phenotype occurred independent of ion-conduction blockade ("no gating pore currents detected"), i.e., a non-conducting, structural/developmental toxicity of the mutant protein compounds the electrophysiological loss of function. The authors conclude "MEAK may be described as a developmental dendritopathy." 5. Network/circuit consequence: loss of fast-spiking PV+ interneuron function and cerebellar Kv3.1-dependent output produces network disinhibition — reduced GABAergic inhibitory tone in cortex, and disrupted cerebellar Purkinje/deep cerebellar nuclei output governing motor coordination. 6. Clinical manifestation: cortical disinhibition and impaired high-frequency interneuron firing manifest as cortical myoclonus and generalized epilepsy; cerebellar circuit dysfunction manifests as progressive ataxia and cerebellar atrophy on imaging.

Mouse model confirmation (in vivo): A knock-in Kcnc1-p.Arg320His/+ heterozygous mouse recapitulates core EPM7 features — progressive ataxia and increased seizure susceptibility. Studies in adult heterozygous mice showed loss of Kv3.1 function "alters excitability and synaptic neurotransmission" in both cerebral cortex PV+ interneurons and cerebellar granule cells. A parallel Kcnc1-p.Ala421Val transgenic mouse model shows even more severe loss of Kv3.1 function, with decreased PV-interneuron surface channel expression, decreased voltage-gated K⁺ current density, profound impairment of PV-interneuron intrinsic excitability, cognitive impairment, epilepsy, and premature lethality — mechanistically consistent with its more severe, earlier-onset DEE phenotype in humans (eLife 2024/2025 preprint/PMC12916103; bioRxiv 10.1101/2024.09.27.615463).

Nonsense/haploinsufficiency mechanism (p.Arg339*): distinct from the dominant-negative missense mechanism — the premature stop codon triggers nonsense-mediated decay, reducing KCNC1 transcript by >50% in patient fibroblasts without producing a dominant-negative truncated protein. This simple haploinsufficiency is proposed to explain the milder, seizure-free ID phenotype, potentially via disrupted non-canonical roles of Kv3.1 in cell proliferation, migration, and neuronal growth-cone dynamics during brain development, rather than through mature-neuron hyperexcitability defects.

Cell types involved (suggested CL terms — verify before curation): fast-spiking parvalbumin-positive GABAergic interneuron (cerebral cortex); cerebellar granule cell (CL:0001031, suggested); Purkinje cell (CL:0000121, suggested); deep cerebellar nuclei neurons.

Biological processes (suggested GO terms — verify before curation): GO:0006813 (potassium ion transport); GO:0005249 (voltage-gated potassium channel activity); regulation of neuronal action potential/high-frequency firing; GABAergic synaptic transmission; neurite/dendrite development; apoptotic process (developmental interneuron death).

Molecular profiling / advanced technologies: No transcriptomic, proteomic, metabolomic, or single-cell/spatial datasets specific to human KCNC1-related PME were identified in this search; the mechanistic data derive from heterologous electrophysiology (Xenopus oocytes, mammalian cell lines), primary neuronal culture, and knock-in/transgenic mouse models rather than -omics profiling.

7. Anatomical Structures Affected

Organ level: Central nervous system exclusively — cerebellum (ataxia, cerebellar atrophy) and cerebral cortex (myoclonus, seizures). No consistent extra-neurological organ involvement is described for classic MEAK; DEE cases can show secondary feeding/growth problems (failure to thrive) as a consequence of severe encephalopathy rather than primary organ pathology.

Body systems: Nervous system (primary); secondary musculoskeletal effects of progressive ataxia (gait impairment, wheelchair dependence).

Tissue/cell level: - Cerebellar cortex: Purkinje cells and granule cells (high Kv3.1/Kv3.3 expression, critical for cerebellar output and motor coordination) - Cerebral cortex: parvalbumin-positive (PV+) fast-spiking GABAergic interneurons (high Kv3.1/Kv3.2 expression, critical for cortical inhibitory tone and network synchrony) - Deep cerebellar nuclei (relay of Purkinje output)

Subcellular level (suggested GO Cellular Component terms — verify): plasma membrane (voltage-gated channel localization); dendrites/neurites (site of the developmental dendritopathy phenotype); growth cone (proposed site of non-canonical Kv3.1 function relevant to the haploinsufficiency ID phenotype).

Anatomical localization (suggested UBERON terms — verify): UBERON:0002037 (cerebellum); UBERON:0002771 (cerebellar cortex); UBERON:0000956 (cerebral cortex); UBERON:0000955 (brain).

Lateralization: Bilateral/symmetric — myoclonus, ataxia, and cerebellar atrophy are described as generalized/bilateral, consistent with a diffuse channelopathy rather than a focal lesion.

8. Temporal Development

Onset: - MEAK/EPM7 (classic form): Insidious, childhood-to-adolescent onset. Myoclonus typically begins age 6–14 years (mean ~10); one detailed case documented intention tremor from age 4–5 progressing to myoclonic jerks and ataxia, with first generalized tonic-clonic seizure at age 22. - DEE form: Acute/early — infantile onset, typically before 10 months of age, with drug-resistant epilepsy as the presenting feature alongside global developmental delay. - Milder ID/isolated-myoclonus phenotypes: Developmental delay apparent in infancy/early childhood; myoclonus can be present from an early age but non-progressive.

Progression: - MEAK is explicitly progressive: myoclonus becomes increasingly severe and disabling through adolescence, ataxia worsens, and roughly half of patients become dependent on a walking aid or wheelchair by late adolescence/early adulthood. Mild cognitive decline can occur after seizure onset in about half of patients, but frank dementia is not reported. - DEE is a static-to-progressive encephalopathy — epilepsy is drug-resistant from infancy, and ataxia/myoclonus in this group are generally non-progressive, distinguishing it mechanistically and prognostically from MEAK despite both arising from KCNC1 loss of function. - Milder ID phenotypes (e.g., p.Arg339) are non-progressive*; no developmental regression reported.

Disease course pattern: Chronic, lifelong, and (in MEAK) progressive; not relapsing-remitting. Rare reports of partial symptomatic improvement with targeted treatment (e.g., DBS reducing myoclonus by 30–100% per prior case-series data cited in the MEAK DBS report) represent treatment response rather than spontaneous remission.

Critical periods: The "developmental dendritopathy" mechanism suggests a developmental window during interneuron maturation (dendritic outgrowth, viability) is specifically vulnerable to R320H toxicity — a potential mechanistic explanation for why the phenotype, though genetically present from conception, manifests progressively over childhood/adolescence as circuit maturation proceeds and interneuron networks are increasingly stressed.

9. Inheritance and Population

Epidemiology: EPM7 is an ultra-rare disease. GeneReviews states approximately 60 individuals with a KCNC1-related disorder have been reported in the literature to date (across the full phenotypic spectrum — MEAK, DEE, and milder ID/myoclonus phenotypes). GeneReviews further estimates the specific MEAK-causing c.959G>A allele arises at a rate of roughly 1 per 5,700,000 conceptions. No formal point-prevalence or incidence figure (e.g., Orphanet prevalence class) was located in this search; the disease should likely be classified in the "not yet documented" / ultra-rare Orphanet prevalence band pending a dedicated epidemiological study.

Inheritance pattern: Autosomal dominant (AD). The overwhelming majority of cases are de novo. Rare instances of transmission from a parent are attributable to germline/somatic mosaicism in an otherwise unaffected or subtly-affected parent (documented for p.Arg320His; PMID: 29428275) rather than to reduced penetrance in a fully heterozygous parent — i.e., true inherited transmission from a fully affected, non-mosaic parent has not been well documented, consistent with the severity of the phenotype limiting reproductive fitness.

Penetrance: The recurrent p.Arg320His variant is described as producing a "highly penetrant and specific" MEAK phenotype (PMID: 25401298) — i.e., essentially full penetrance for the classic syndrome when present in non-mosaic heterozygous form.

Expressivity: Variable across the KCNC1 allelic series — the same gene produces phenotypes ranging from isolated non-progressive myoclonus to severe infantile DEE to progressive MEAK to ID without seizures, depending on the specific variant and its precise functional consequence (simple loss of function vs. dominant-negative vs. haploinsufficiency). Within the MEAK/R320H group specifically, expressivity is comparatively consistent (a defined triad of myoclonus–seizures–ataxia).

Genetic anticipation: Not reported/not applicable — this is not a repeat-expansion disorder.

Germline/somatic mosaicism: Documented and clinically important (see Etiology and Genetics sections) — critical for accurate genetic counseling, since an apparently sporadic de novo case in a family can recur in a subsequent pregnancy if a parent carries low-level mosaicism.

Founder effects / consanguinity / carrier frequency: No founder populations or consanguinity association reported — consistent with a dominant, essentially always de novo disorder rather than a recessive trait with population-specific carrier frequency. There is no meaningful "carrier frequency" concept for this AD, near-fully-penetrant, mostly de novo disease.

Population demographics: No specific ethnic, geographic, or sex-ratio predilection was identified in the literature reviewed; cases have been reported from multiple exome-sequencing cohorts internationally (the original Muona et al. 2015 discovery cohort drew from an international collection of 84 unrelated PME cases of unknown etiology). No age-distribution skew beyond the expected childhood/adolescent (MEAK) vs. infantile (DEE) onset windows described above.

10. Diagnostics

Establishing the diagnosis: Per GeneReviews, "the diagnosis of KCNC1-related disorders is established in a proband with suggestive findings and a heterozygous pathogenic variant in KCNC1 identified by molecular genetic testing."

Genetic testing approach: - Preferred first-tier test: a multigene epilepsy/PME panel (including KCNC1 along with other PME genes) or comprehensive exome/genome sequencing, given the phenotypic overlap with other PME etiologies. - Single-gene KCNC1 testing is not recommended as a first step given genetic heterogeneity of PME. - Variants of uncertain significance (e.g., p.Ala513Val) do not, by themselves, establish the diagnosis. - Parental testing (including assessment for low-level mosaicism where feasible) is recommended for accurate recurrence-risk counseling once a proband variant is identified.

Clinical/electrophysiological tests: - EEG: abnormal/epileptiform in ~87% of reported KCNC1-PME cases; generalized spike-and-polyspike-wave discharges; documented photosensitivity (photoparoxysmal response) in most cases; some individual case reports document a normal EEG despite a molecularly confirmed diagnosis, so a normal EEG does not exclude the disease. - Neurological examination: mild cognitive decline, dysmetria, horizontal gaze-evoked nystagmus, truncal ataxia, bilateral upper-limb myoclonic jerks are typical exam findings.

Neuroimaging: Brain MRI shows cerebellar atrophy in about a third of cases (32.6%, 15/46 in a pooled case series) — a supportive but not obligatory finding; a normal MRI does not exclude EPM7.

Differential diagnosis (per GeneReviews, for the PME/MEAK presentation): - Progressive myoclonic epilepsy type 1 (EPM1, Unverricht-Lundborg disease; CSTB) - Lafora disease (EPM2A/EPM2B; NHLRC1) - Neuronal ceroid lipofuscinoses (NCLs) - MERRF (mitochondrial, m.8344A>G and related) - POLG-related disorders - Sialidosis - Dentatorubral-pallidoluysian atrophy (DRPLA) - PRICKLE1-related progressive myoclonic epilepsy - KCTD7-related progressive myoclonic epilepsy (a molecularly and clinically distinct PME gene, per PME literature — not to be confused with KCNC1 despite superficial acronym similarity) - For the DEE and milder ID/DD phenotypes, the differential is broad and nonspecific, requiring genomic-first diagnostic approaches (per the OMIM phenotypic-series framework for developmental encephalopathies).

Omics-based diagnostics: No routine transcriptomic/proteomic/metabolomic/epigenomic diagnostic assay is used clinically for KCNC1-related disorders; diagnosis is DNA-sequencing based.

Screening: No population or newborn screening program exists for this ultra-rare, typically de novo disorder; screening is not applicable outside of diagnostic testing in a symptomatic proband and subsequent targeted parental/reproductive counseling.

11. Outcome / Prognosis

Survival/mortality: GeneReviews states MEAK "does not appear to impact life span" — i.e., despite major morbidity, life expectancy in the classic MEAK phenotype is not reported to be shortened. This contrasts with the DEE phenotype, where severe infantile-onset drug-resistant epilepsy and profound developmental impairment carry greater overall morbidity, though specific mortality/life-expectancy statistics for the DEE subgroup were not identified in this search (the A421V transgenic mouse model does show premature lethality, but this has not been explicitly quantified in human DEE cohorts in the sources reviewed).

Morbidity/function: Major functional morbidity in MEAK arises from progressive ataxia (approximately half of patients require a walking aid or wheelchair by late adolescence/early adulthood) and from disabling action myoclonus that impairs voluntary movement, self-care, and mobility. No dementia has been reported, distinguishing the cognitive trajectory from many other PMEs (e.g., Lafora disease, which is far more rapidly and severely cognitively devastating).

Disease course/complications: Recurrent generalized tonic-clonic seizures (infrequent but present in ~97%) carry standard epilepsy-associated risks (injury, and — as with any epilepsy — a background SUDEP consideration, though this was not specifically quantified for KCNC1-PME in the sources reviewed). In DEE, feeding difficulties and failure to thrive are a recognized complication requiring supportive intervention (feeding therapy, gastrostomy).

Recovery potential: The disease is not self-limited; there is no spontaneous recovery. Targeted interventions (deep brain stimulation, investigational Kv3 modulator therapy — see Treatment) show partial symptomatic benefit in reported cases/trials but are not curative.

Prognostic factors: The single most important prognostic determinant identified in this literature is genotype — which specific KCNC1 variant, and its precise functional mechanism (classic dominant-negative R320H → MEAK; more severe near-complete loss-of-function A421V → infantile DEE; haploinsufficiency nonsense variants → milder ID without seizures) — rather than any independently measured biomarker.

12. Treatment

Pharmacotherapy (symptomatic anti-seizure/anti-myoclonic management): There is no KCNC1-specific approved anti-seizure medication; management uses conventional PME-appropriate agents: - Valproic acid and clonazepam are traditionally considered first-line for PME-associated myoclonus and seizures. - Levetiracetam, piracetam, and topiramate are also reported as effective adjuncts for myoclonus in the broader PME literature and are used in KCNC1-related disorders. - Perampanel has shown benefit for cortical myoclonus in progressive myoclonic epilepsies generally (including case series/systematic review data in PME broadly, e.g., PMID: 25667843 for Lafora disease and a broader PME case series/review, PMC8024635), though psychiatric/behavioral side effects can limit its use. - Primidone is also listed among conventional ASMs considered for myoclonus in KCNC1-related disorders per GeneReviews. - Contraindicated/to-avoid agents: consistent with general PME pharmacology, sodium-channel blockers and GABAergic-potentiating drugs that can worsen myoclonus/PME phenotypes should be avoided — phenytoin, carbamazepine, gabapentin, and vigabatrin are specifically flagged as agents to avoid in progressive myoclonic epilepsies. - Suggested NCIT term: NCIT:C15986 (Pharmacotherapy), with therapeutic_agent bindable to CHEBI terms for valproic acid, clonazepam, levetiracetam, perampanel, topiramate (exact CHEBI IDs should be independently verified via OAK before KB entry, per dismech SOP).

Genotype-informed / emerging pharmacotherapy: - Fluoxetine showed clinical benefit (improved seizures, balance, motor skills) in one reported DEE patient with a gain-of-function-adjacent KCNC1 variant (c.1273G>A) — a preliminary, single-case observation rather than an established treatment. - AUT00201, a novel Kv3 modulator developed by Autifony Therapeutics, directly targets the disease mechanism: preclinical data show it can restore Kv3.1 channel function in cell lines expressing mutant channels, improve firing of neurons in mouse-model brains, and "completely reverse the seizure sensitivity and ataxia" of KCNC1 mouse models in vivo. A US Phase Ib randomized, double-blind, placebo-controlled crossover study in adults (≥18 years) with genetically confirmed MEAK commenced in 2023 at the University of Pennsylvania (ClinicalTrials.gov NCT05873062), assessing both clinical endpoints (ataxia, myoclonus) and Kv3.1-dysfunction biomarkers; the study is reported complete with data analysis ongoing as of the sources reviewed. This represents the first disease-mechanism-targeted (rather than purely symptomatic) therapeutic approach in clinical development for EPM7.

Neuromodulation/surgical: - Deep brain stimulation (DBS) of the subthalamic nucleus/substantia nigra (STN/SNr) has been reported in a genetically confirmed MEAK patient with pharmacoresistant myoclonus and drug-resistant epilepsy, with SNr/STN stimulation reported to reduce myoclonic seizures by 30–100% based on prior case-series data cited in that report (PMID/PMC: 10624572). This is an individualized, refractory-case intervention rather than standard of care.

Supportive/rehabilitative care: - Physical and occupational therapy for progressive ataxia and motor dysfunction. - Feeding therapy/gastrostomy for infants with DEE-associated feeding difficulties and failure to thrive. - Standard epilepsy monitoring and safety counseling; educational and developmental support services, particularly for the DEE and ID phenotypes. - Genetic counseling for families (NCIT:C15240, suggested).

Experimental/clinical trials: AUT00201 Phase Ib (NCT05873062) is the principal disease-specific interventional trial identified.

Treatment strategy: Progressive myoclonic epilepsies in general (including KCNC1-related PME) are "best treated by polytherapy" rather than monotherapy, combining conventional ASMs targeted at both the seizure and myoclonus components of the phenotype, with emerging genotype/mechanism-targeted approaches (Kv3 modulation, and case-specific SSRI or DBS trials) reserved for refractory cases.

13. Prevention

Because EPM7/KCNC1-related disorders arise almost exclusively from de novo dominant mutation, there is no primary population-level prevention strategy (no modifiable risk-factor reduction, immunization, or public-health intervention applies to a de novo monogenic channelopathy).

• Secondary prevention / risk stratification: the main actionable prevention lever is genetic counseling informed by parental mosaicism testing. Because low-level parental germline/somatic mosaicism has been documented to cause recurrence in siblings despite an apparently unaffected parent (PMID: 29428275), families should be counseled that recurrence risk is not simply the general de novo background rate once a variant is identified in a proband — targeted, sensitive mosaicism testing in parents (where technically available) refines recurrence-risk estimates for future pregnancies.
• Prenatal/preimplantation genetic testing: once a familial pathogenic variant is known (including in a mosaic parent), prenatal diagnosis or preimplantation genetic testing for monogenic disease (PGT-M) would be a standard reproductive option discussed in genetic counseling, though no disease-specific PGT program was identified in this search.
• Tertiary prevention: early diagnosis (via genomic-first testing given the nonspecific/overlapping PME phenotype) allows earlier initiation of appropriate anti-myoclonic/anti-seizure therapy and avoidance of contraindicated ASMs (phenytoin, carbamazepine, gabapentin, vigabatrin), which is the most concrete disease-specific "prevention of harm" measure identifiable in the current literature.
• No vaccine, prophylactic medication, or environmental-exposure-avoidance strategy applies, consistent with the absence of any identified environmental or infectious contributory factor.

14. Other Species / Natural Disease

No literature identified in this search describes a naturally occurring (spontaneous, non-engineered) KCNC1-associated disease in a non-human species (companion animal, livestock, or wildlife) analogous to OMIA-catalogued veterinary orthologs of human Mendelian disease. All non-human Kcnc1 disease models identified are laboratory-engineered (see Model Organisms, below), not naturally occurring veterinary conditions. The gene is broadly conserved across mammals (mouse Kcnc1 ortholog is the model used in essentially all functional/in vivo work reviewed here), consistent with deep evolutionary conservation of Kv3-family channel biology across vertebrates, but no comparative/zoonotic transmission relevance applies, since this is a non-communicable monogenic channelopathy.

• Taxonomy: Human, NCBITaxon:9606. Mouse ortholog Kcnc1 used throughout functional/model studies (Mus musculus, NCBITaxon:10090).
• Breed-specific veterinary disease: none identified.
• Zoonotic potential / cross-species transmission: not applicable (non-infectious monogenic disease).

15. Model Organisms

Genetic mouse models (the dominant model system for this disease):

1. Kcnc1-p.Arg320His/+ knock-in mouse (heterozygous) — recapitulates the core features of EPM7/MEAK: progressive ataxia and increased seizure susceptibility. Electrophysiological studies in adult heterozygous mice demonstrate that loss of Kv3.1 function alters excitability and synaptic neurotransmission in cerebral cortex PV+ interneurons and cerebellar granule cells, mirroring the proposed human disease mechanism. This model was used to demonstrate that the investigational Kv3 modulator AUT00201 can "completely reverse the seizure sensitivity and ataxia" in vivo, supporting its translation to the human Phase Ib trial (NCT05873062).

2. Kcnc1-p.Ala421Val transgenic mouse (global heterozygous expression) — models the DEE end of the spectrum. Shows cognitive impairment, epilepsy, and premature lethality, with decreased PV-interneuron surface Kv3.1 expression, decreased voltage-gated K⁺ current density, and profound impairment of PV-interneuron intrinsic excitability — a more severe cellular/electrophysiological phenotype than the R320H model, consistent with A421V's more severe human clinical phenotype (earlier-onset, treatment-resistant epilepsy). Described in "Impaired excitability of fast-spiking neurons in a novel mouse model of KCNC1 epileptic encephalopathy" (eLife, 2024/2025; PMC12916103, PMC11463657, and the bioRxiv preprint 10.1101/2024.09.27.615463).

3. Kcnc1/Kcnc3 compound-null mice (an earlier, mechanistically informative but not disease-variant-specific model): mice lacking Kcnc1 alleles on a Kcnc3-null background show progressively worsening gait ataxia, spike broadening, and deceleration in deep cerebellar nuclei (DCN) neurons as Kcnc1 alleles are lost; Purkinje-cell-targeted restoration of Kv3.3 (Kcnc3) does not rescue motor coordination in the absence of Kcnc1, underscoring the essential, non-redundant contribution of Kv3.1 to cerebellar output pathways governing motor coordination (Purkinje cell → deep cerebellar nuclei → downstream motor circuits) (Espinosa et al., J Neurosci 2009; PMID: 20016089). This model validates the general biological logic (loss of Kv3.1-dependent high-frequency firing in cerebellar circuits → ataxia) rather than directly modeling a specific human pathogenic allele.

In vitro/cellular models: - Primary mouse cortical interneuron culture (postnatal day 0–1, C57BL/6J) with lentiviral/plasmid expression of mutant Kv3.1bR320H — used to establish the "developmental dendritopathy" mechanism (impaired neurite outgrowth, reduced high-frequency firing capacity, increased apoptosis) (Carpenter et al., Epilepsia 2021; PMID: 33735526). - Xenopus laevis oocyte heterologous expression system — used across multiple studies (Muona 2015, Oliver 2017/Ann Neurol, Muona/Oliver 2019 series) for direct biophysical characterization of mutant Kv3.1 channel currents, dominant-negative behavior in co-expression with wild-type subunit, and comparison across the allelic series (R320H, A421V, C208Y, T399M, R339, etc.). - Patient fibroblast qPCR — used to demonstrate nonsense-mediated decay and haploinsufficiency for the p.Arg339 variant.

Model characteristics/limitations: The R320H knock-in mouse is considered a high-fidelity model of MEAK, recapitulating both the ataxia and seizure-susceptibility phenotypes and validated as a translational platform for the AUT00201 Kv3-modulator program. The A421V model appropriately captures the more severe DEE phenotype including premature lethality. No invertebrate (Drosophila, C. elegans) or zebrafish kcnc1 disease models were identified in this search (zebrafish kcna1a models exist for a related but distinct potassium-channel epilepsy, episodic ataxia type 1, and should not be conflated with KCNC1/EPM7).

Applications: These models have been directly used for (a) confirming causal genotype-phenotype-mechanism relationships, (b) dissecting cell-type-specific (cortical PV-interneuron vs. cerebellar granule/Purkinje) contributions to the myoclonus-ataxia phenotype, and (c) preclinical validation and translational bridging for the Kv3-modulator (AUT00201) therapeutic program now in human Phase Ib testing.

Summary Table: Key Ontology Term Suggestions for KB Curation

(All IDs below are provided as starting-point suggestions from research-report synthesis and should be independently verified via OAK/authoritative ontology browsers before use in curation, per standard anti-hallucination practice — several, particularly the CL, GO, and HPO codes, are recalled with lower confidence than the disease/gene identifiers.)

Sources

• Entry - #616187 - EPILEPSY, PROGRESSIVE MYOCLONIC 7; EPM7 - OMIM
• Entry - *176258 - POTASSIUM CHANNEL, VOLTAGE-GATED, SHAW-RELATED SUBFAMILY, MEMBER 1; KCNC1 - OMIM
• Orphanet: Progressive myoclonic epilepsy type 7
• KCNC1-Related Disorders - GeneReviews® - NCBI Bookshelf
• A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy - PubMed (Muona et al., Nat Genet 2015; PMID 25401298)
• Familial cases of progressive myoclonic epilepsy caused by maternal somatic mosaicism of a recurrent KCNC1 p.Arg320His mutation - PubMed (PMID 29428275)
• Progressive myoclonus epilepsy KCNC1 variant causes a developmental dendritopathy - PMC (Carpenter et al., Epilepsia 2021; PMID 33735526)
• Loss of Function of KCNC1 is associated with intellectual disability without seizures - PMC
• KCNC1-related disorders: new de novo variants expand the phenotypic spectrum - PubMed (PMID 31353862)
• Encephalopathies with KCNC1 variants: genotype-phenotype-functional correlations - PubMed (PMID 31353855)
• Impaired excitability of fast-spiking neurons in a novel mouse model of KCNC1 epileptic encephalopathy - eLife/PMC
• Targeted therapy improves cellular dysfunction, ataxia, and seizure susceptibility in a model of a progressive myoclonus epilepsy - ScienceDirect
• Rescue of Motor Coordination by Purkinje Cell-Targeted Restoration of Kv3.3 Channels in Kcnc3-Null Mice Requires Kcnc1 - PubMed (PMID 20016089)
• Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)
• Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK - ClinicalTrials.gov protocol (NCT05873062)
• Deep brain stimulation in a patient with progressive myoclonic epilepsy and ataxia due to potassium channel mutation (MEAK). A case report and review of the literature - PMC
• Myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK) is caused by heterozygous KCNC1 mutations - Epileptic Disorders (Nascimento et al., 2016)
• KCNC1 ‐Related Progressive Myoclonus Epilepsy: A Case Report - PMC
• Kv3 Channels: Enablers of Rapid Firing, Neurotransmitter Release, and Neuronal Endurance - Physiological Reviews
• Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature - PMC
• KCNC1 gene - GeneCards

Progressive Myoclonic Epilepsy Type 7 (EPM7 / MEAK): Comprehensive Disease Characteristics Report

Disease: Progressive Myoclonic Epilepsy Type 7 (EPM7) Clinical eponym/synonym: Myoclonus Epilepsy and Ataxia due to potassium channel mutation (MEAK) Key identifiers: OMIM #616187 · MONDO:0014734 · ORPHA:280620 · Gene: KCNC1 (Kv3.1) Category: Genetic (autosomal dominant, de novo)

Summary

Progressive Myoclonic Epilepsy Type 7 (EPM7), better known by its clinical descriptor Myoclonus Epilepsy and Ataxia due to potassium channel mutation (MEAK), is a rare, progressive neurodegenerative epilepsy caused almost exclusively by a single recurrent de novo heterozygous variant in the KCNC1 gene, c.959G>A (p.Arg320His). KCNC1 encodes Kv3.1, a voltage-gated potassium channel subunit that endows fast-spiking neurons with the rapid membrane repolarization needed to sustain high-frequency firing. The R320H substitution sits in the S4 voltage-sensor and acts through a dominant-negative loss-of-function mechanism, poisoning heterotetrameric channels and reducing Kv3.1 current well below the 50% expected from simple haploinsufficiency. In the landmark exome study of 84 unrelated patients with previously unexplained progressive myoclonus epilepsy (PME), this one variant explained 13% of cases, establishing KCNC1 as a major cause of the disorder (PMID: 25401298).

Clinically, MEAK begins in childhood or early adolescence (symptom onset 3–15 years, median 9.5 years) with progressively disabling cortical action myoclonus, relatively infrequent tonic-clonic seizures, early and prominent cerebellar ataxia, and symmetrical, progressive cerebellar atrophy on MRI. Roughly half of patients become wheelchair-bound by late adolescence, and mild cognitive decline occurs in about half; unlike some other PMEs, early death is not characteristic. A striking and diagnostically useful feature is transient clinical improvement with fever, which has a mechanistic explanation: elevated temperature produces a leftward (hyperpolarizing) shift in Kv3.1 activation that partially rescues channel availability (PMID: 28380698).

The pathophysiology is a channelopathy of fast-spiking neurons. Loss of Kv3.1 function impairs high-frequency firing of cortical fast-spiking GABAergic interneurons (producing cortical disinhibition → myoclonus and generalized seizures) and of cerebellar neurons (producing ataxia and tremor), and can induce neuronal cell death; the R320H allele additionally causes a developmental dendritopathy, indicating a role beyond firing regulation. Treatment is entirely symptomatic — valproate, levetiracetam, clonazepam, perampanel — with strict avoidance of myoclonus-aggravating sodium-channel blockers and related drugs; no disease-modifying therapy exists, though Kv3 positive modulators are a rational emerging strategy motivated by cryo-EM structures of the human Kv3.1 gating machinery.

Section 1 — Disease Information

Overview. EPM7/MEAK is a monogenic progressive myoclonus epilepsy: a syndrome combining action myoclonus, epileptic seizures, and progressive neurological decline (here dominated by cerebellar ataxia). It is caused by dysfunction of the Kv3.1 voltage-gated potassium channel. It is characterized as "a highly penetrant and specific form of progressive myoclonus epilepsy with severe ataxia, designated myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK)" (PMID: 33735526).

Key identifiers.

Synonyms / alternative names. EPM7; Myoclonus Epilepsy and Ataxia due to potassium channel mutation (MEAK); KCNC1-related progressive myoclonus epilepsy; KCNC1-related disorder (MEAK subtype).

Source of information. The knowledge base is derived from aggregated disease-level resources and published patient cohorts (exome-sequencing discovery cohorts and case series), not individual EHR data. Primary evidence sources are human clinical cohorts, in vitro electrophysiology (heterologous expression / patch-clamp), and, more recently, mouse models and cryo-EM structural biology.

Section 2 — Etiology

Primary cause (genetic). EPM7/MEAK is caused by a recurrent de novo heterozygous mutation, c.959G>A (p.Arg320His), in KCNC1, which "was identified as a new major cause for PME" (PMID: 25401298). The variant maps to chromosome 11 and "encodes for the Kv3.1 protein" (PMID: 27629860). The disorder is essentially always sporadic, arising de novo in the affected individual.

Genetic risk factors. The single causal variant (R320H) is the dominant genetic determinant; there are no known susceptibility loci or modifier genes established for MEAK. Because the variant is a recurrent de novo germline change, there is effectively no population carrier state and it is absent from population frequency databases (gnomAD).

Environmental risk factors. None established. MEAK is a Mendelian channelopathy; environmental exposures are not causal. Fever/elevated body temperature acts paradoxically as a transient symptom modifier (improvement), not a risk factor (PMID: 28380698).

Protective factors. No genetic protective variants or modifier alleles are described. The best-characterized modifier is a physiological one: elevated temperature transiently improves symptoms via a leftward shift in Kv3.1 activation.

Gene–environment interactions. The only well-documented gene–environment interaction is temperature × channel gating: the R320H dominant-negative deficit is partially offset at higher temperature because wild-type Kv3.1 activation shifts to more hyperpolarized voltages, increasing channel availability (PMID: 28380698).

Section 3 — Phenotypes

Core phenotypes (from the 20-patient R320H cohort, PMID: 28380698; mechanism review PMID: 27629860):

Supporting quotes: "Symptoms began at between 3 and 15 years of age (median = 9.5), with progressively severe myoclonus and rare tonic-clonic seizures"; "Magnetic resonance imaging revealed symmetrical cerebellar atrophy, which appeared progressive"; "transient clinical improvement with fever was noted in 6 patients" (PMID: 28380698).

Quality-of-life impact. Progressive action myoclonus and ataxia severely impair mobility, self-care, and independence; approximately half of patients require a wheelchair by late adolescence. Cognitive decline, where present, is generally mild. Early death is not a characteristic feature, so the dominant burden is chronic disability rather than mortality.

Section 4 — Genetic / Molecular Information

Causal gene. KCNC1 (HGNC:6233; OMIM 176258), encoding the Kv3.1* voltage-gated potassium channel subunit, which determines high-frequency firing in neurons.

Pathogenic variant (MEAK-defining).

"Functional analysis of the Arg320His mutant channel showed a dominant-negative loss-of-function effect" (PMID: 25401298).

Broader KCNC1 allelic series (genotype–phenotype spectrum). MEAK is one end of a spectrum of KCNC1-related neurological disease:

"either isolated nonprogressive myoclonus (p.Cys208Tyr), intellectual disability (p.Thr399Met), or epilepsy with myoclonic, absence and generalized tonic-clonic seizures, ataxia, and developmental delay (p.Ala421Val, three patients)" and "Functional analyses demonstrated no measurable currents for all identified variants and dominant-negative effects for p.Thr399Met and p.Ala421Val predicting neuronal disinhibition as the underlying disease mechanism" (PMID: 31353862). A gain-of-function subgroup with "a prominent leftward (hyperpolarized) shift in the voltage dependence of activation" is associated with DD/ID and central hypotonia without epilepsy or ataxia (PMID: 36419348). The p.Thr399Met variant illustrates a "dominant-positive effect" — complete LoF alone but a ∼20 mV hyperpolarizing shift with slowed deactivation when co-expressed with WT (PMID: 42347804).

Modifier genes / epigenetics / chromosomal abnormalities. None established for MEAK. The disease is a single-gene channelopathy without a described epigenetic component or large-scale structural/chromosomal etiology.

Section 5 — Environmental Information

Environmental factors. None causal. MEAK is a de novo monogenic disorder.

Lifestyle factors. No lifestyle behaviors are established as causing or preventing MEAK. As with other myoclonic epilepsies, general seizure-precipitant avoidance (sleep deprivation, photic triggers) is prudent; EEG photosensitivity is present in many patients.

Infectious agents. Not applicable — MEAK is genetic, not infectious. Notably, febrile illness transiently improves symptoms in a subset of patients (a physiological, not infectious, effect on channel gating) (PMID: 28380698).

Section 6 — Mechanism / Pathophysiology

Central mechanism. Kv3.1 is a delayed-rectifier potassium channel with distinctive fast activation/deactivation kinetics tailored for rapid repolarization in fast-spiking neurons. The MEAK R320H variant, positioned in the S4 voltage sensor, produces channels that assemble with wild-type subunits but abolish current — a dominant-negative loss of function that reduces Kv3.1-mediated repolarization more than haploinsufficiency would.

Causal chain (upstream → downstream):

KCNC1 c.959G>A (p.Arg320His), de novo, heterozygous   [upstream trigger]
│
▼
Dominant-negative poisoning of Kv3.1 heterotetramers → loss of fast K+ current
│
├──► Fast-spiking GABAergic interneurons fail to sustain high-frequency firing
│           → cortical DISINHIBITION → cortical (action) myoclonus + generalized seizures
│
├──► Cerebellar neurons impaired → ATAXIA, tremor; progressive cerebellar atrophy
│
└──► Developmental DENDRITOPATHY + neuronal cell death   [additional/parallel]
│
▼
Progressive, disabling clinical MEAK phenotype        [downstream manifestation]

Supporting statements: "Loss of Kv3 function disrupts the firing properties of fast-spiking neurons, affects neurotransmitter release and induces cell death" and "the most affected neurons include inhibitory GABAergic interneurons and cerebellar neurons. Impairment of the former cells is believed to contribute to myoclonus and seizures, whereas dysfunction of the latter to ataxia and tremor" (PMID: 27629860). The R320H allele additionally "causes a developmental dendritopathy", indicating a role beyond high-frequency firing regulation (PMID: 33735526). A 2026 mouse model of the recurrent variant shows impaired excitability of fast-spiking neurons (PMID: 41705663).

Structural basis of gating. Cryo-EM of human Kv3.1a reveals a unique cytoplasmic T1 tetramerization domain interacting with the C-terminal axonal-targeting motif and gating machinery; S1/S2-linker–turret interactions strengthen the voltage-sensor–pore interface, and an electrostatic α6(T1)–R449(S6T) contact plus S4/S5-linker residues control the channel's fast gating. "Malfunction of this process due to genetic variants in the KCNC1 gene causes severe epileptic disorders" and the structures "provide insights into gating control and disease mechanisms and may guide strategies for the design of pharmaceutical drugs targeting Kv3 channels" (PMID: 35840580).

Temperature dependence (fever improvement). "At elevated temperatures, there was a robust leftward shift in activation of wild-type K[v3.1]" — increased channel availability that can partially offset the R320H deficit, explaining transient fever-associated improvement (PMID: 28380698).

Ontology suggestions. - GO (biological process): potassium ion transmembrane transport (GO:0071805); regulation of membrane potential (GO:0042391); action potential (GO:0001508); regulation of neuronal action potential (GO:0098908). - GO (cellular component): voltage-gated potassium channel complex (GO:0008076); plasma membrane (GO:0005886); axon (GO:0030424); neuronal dendrite (GO:0030425). - CHEBI: potassium(1+) (CHEBI:29103). - CL (cell types): cerebellar Purkinje cell (CL:0000121); GABAergic interneuron (CL:0000617); fast-spiking basket cell / cortical interneuron.

Immune, metabolic, and fibrotic mechanisms are not implicated; MEAK is a primary neuronal channelopathy.

Section 7 — Anatomical Structures Affected

Organ / body system level. Primary organ: brain (central nervous system). Chiefly affected regions are the cerebral cortex (fast-spiking interneurons → myoclonus/seizures) and the cerebellum (ataxia and progressive symmetrical atrophy). Body system: nervous system (UBERON:0001016). No primary involvement of non-neural organs.

Tissue / cell level. Nervous tissue; specifically fast-spiking GABAergic inhibitory interneurons of cortex and cerebellar neurons (including Purkinje-cell circuitry). "the most affected neurons include inhibitory GABAergic interneurons and cerebellar neurons" (PMID: 27629860).

Subcellular level. The neuronal plasma membrane (voltage-gated K+ channel complex), axon (Kv3.1 axonal targeting motif), and dendrites (developmental dendritopathy, PMID: 33735526). GO cellular components: voltage-gated potassium channel complex (GO:0008076); axon (GO:0030424); dendrite (GO:0030425).

Localization / lateralization. Bilateral and symmetrical — cerebellar atrophy is described as symmetrical and progressive (PMID: 28380698).

UBERON suggestions: brain (UBERON:0000955); cerebellum / cerebellar cortex (UBERON:0002037 / UBERON:0002129); cerebral cortex (UBERON:0000956).

Section 8 — Temporal Development

Onset. Childhood to early adolescence; symptom onset 3–15 years, median 9.5 years (PMID: 28380698). Onset is typically insidious, often initially misdiagnosed as idiopathic generalized epilepsy.

Progression. Chronic and progressive. Myoclonus becomes progressively severe and disabling; ataxia progresses with symmetrical cerebellar atrophy; roughly half of patients lose independent ambulation by late teens. Cognitive decline, when present, is mild. Unlike some PMEs (e.g., Lafora disease), early death is not characteristic of MEAK.

Patterns. No spontaneous remission. A distinctive feature is transient, fluctuating improvement during febrile episodes. The therapeutic critical window and disease-modifying intervention timing remain undefined, though the temperature effect suggests Kv3 augmentation could be beneficial across the disease course.

Section 9 — Inheritance and Population

Inheritance. Autosomal dominant, arising from a de novo heterozygous KCNC1 variant; "caused by a recurrent de novo heterozygous mutation (c.959G>A, p.Arg320His) in the KCNC1 gene, which maps to chromosome 11 and encodes for the Kv3.1 protein" (PMID: 27629860). Essentially all cases are sporadic.

Penetrance / expressivity. Highly penetrant for the R320H allele; the phenotype is relatively specific and stereotyped (MEAK) — "a highly penetrant and specific form of progressive myoclonus epilepsy with severe ataxia" (PMID: 33735526).

Anticipation / mosaicism / founder effects. No genetic anticipation (not a repeat-expansion disorder). Recurrence risk to siblings is low but non-zero due to possible parental gonadal mosaicism. There is no founder population — reported patients span multiple countries and ethnicities.

Carrier frequency. Effectively none — the variant is de novo and germline, absent from population frequency databases (PMID: 25401298; PMID: 27629860).

Epidemiology. Ultra-rare. No precise prevalence/incidence estimate is established, but the disorder is a major molecular cause of otherwise-unexplained PME: R320H accounted for 11/84 (13%) of exome-discovery cases and 2 additional cases (7%) in a secondary cohort — "Eleven unrelated exome-sequenced (13%) and two affected individuals in a secondary cohort (7%) had this mutation" (PMID: 25401298).

Sex ratio / geographic distribution. No strong sex predilection reported; no endemic geographic clustering (no founder effect).

Section 10 — Diagnostics

Diagnostic approach. Molecular confirmation is definitive. Because the disorder is caused predominantly by a single recurrent variant, targeted single-gene / gene-panel testing or exome sequencing for KCNC1 c.959G>A (p.Arg320His) is the key diagnostic test. Early disease is frequently misdiagnosed as idiopathic generalized epilepsy — "the potential for misdiagnosis as idiopathic generalized epilepsy during the early phase of the disease" (PMID: 32972906).

Supportive clinical / electrophysiological features. - Giant (high-amplitude) somatosensory evoked potentials (SEPs) — "abnormally high amplitude in the sensory evoked potential recording" (PMID: 32972906), reflecting cortical hyperexcitability. - Cortical myoclonus confirmed by polygraphic EEG-EMG (short-duration bursts, agonist–antagonist coactivation). - EEG: generalized spike/polyspike-wave discharges with photosensitivity. - MRI: progressive symmetrical cerebellar atrophy (PMID: 28380698).

Differential diagnosis (other PMEs to exclude): Unverricht-Lundborg disease (EPM1, CSTB), Lafora disease (EPM2A/NHLRC1), MERRF (mitochondrial MT-TK), DRPLA (ATN1), sialidosis, and neuronal ceroid lipofuscinoses. Distinguishing features of MEAK: prominent early ataxia with symmetrical cerebellar atrophy, fever-related improvement, absence of dementia/organomegaly, and the specific KCNC1 genotype.

Genetic testing utility. WES/WGS and epilepsy/PME gene panels including KCNC1 are highly effective; single-variant testing is diagnostic given the recurrent allele. CMA, karyotyping, FISH, mtDNA testing, and repeat-expansion testing are not applicable to MEAK (used mainly to exclude mimics). Omics-based diagnostics are not standard.

Section 11 — Outcome / Prognosis

Survival / mortality. MEAK is chronically disabling but, unlike Lafora disease or severe EPM1, early death is not a defining feature; the 20-case series did not report early death as characteristic (PMID: 28380698). No formal 5-/10-year survival statistics are established.

Morbidity / function. The dominant outcome is progressive motor disability: severe action myoclonus and ataxia, with ~half of patients wheelchair-bound by late adolescence. Cognitive decline is generally mild. Quality of life is substantially reduced due to impaired mobility and dependence.

Disease course / complications. Progressive, lifelong. Complications relate to falls, immobility, and drug-refractory myoclonus. Recovery potential is limited; current therapy controls symptoms partially but does not reverse progression.

Prognostic factors. Genotype is the principal determinant — the R320H allele defines the stereotyped MEAK course. Younger onset within the range and rapidly progressive myoclonus/ataxia portend greater disability. No validated molecular prognostic biomarkers exist beyond the causal genotype.

Section 12 — Treatment

No disease-modifying therapy exists. Management is symptomatic anti-myoclonic polytherapy, frequently requiring 3–4 drugs, plus rehabilitation for ataxia.

Pharmacotherapy (PME framework, PMID: 28799509):

"Valproic acid is the drug of choice, except for PMEs due to mitochondrial diseases. Levetiracetam and clonazepam should be considered as the first add-on treatment. Zonisamide and perampanel represent promising alternatives" (PMID: 28799509).

Drugs to AVOID (aggravate myoclonus/seizures): carbamazepine, phenytoin, oxcarbazepine, lamotrigine, vigabatrin, gabapentin, pregabalin. "Avoidance of drugs known to aggravate myoclonus and seizures, such as carbamazepine and phenytoin, is paramount" (PMID: 28799509).

Supportive / rehabilitative care. Physical, occupational, and speech therapy for ataxia and functional decline; mobility aids; falls prevention.

Advanced / experimental therapeutics. No approved gene, cell, or RNA therapy for MEAK. The mechanistically rational emerging strategy is Kv3 channel positive modulation (small-molecule Kv3 openers) to augment residual channel function — motivated by the fever-improvement phenomenon (temperature-induced leftward activation shift, PMID: 28380698) and by cryo-EM structures that "may guide strategies for the design of pharmaceutical drugs targeting Kv3 channels" (PMID: 35840580).

Personalized medicine. Treatment selection is genotype-informed within the KCNC1 spectrum: LoF/dominant-negative MEAK (R320H) is the target for Kv3 openers, whereas gain-of-function KCNC1 variants would require the opposite pharmacological direction — underscoring the need for functional variant characterization (PMID: 35759918).

Section 13 — Prevention

Primary prevention. Not applicable in the classical sense — MEAK arises de novo and cannot be prevented by risk-factor modification. Recurrence risk to future siblings is low (gonadal mosaicism caveat), so genetic counseling is the primary preventive tool.

Secondary prevention / early detection. Early molecular diagnosis (KCNC1 testing in childhood-onset myoclonic epilepsy with ataxia and giant SEPs) enables appropriate drug selection and, critically, avoidance of myoclonus-aggravating drugs, preventing iatrogenic worsening.

Genetic screening. No population carrier screening is warranted (no carrier state). Prenatal/preimplantation testing is generally not applicable given the de novo nature, but is available for recurrence-risk counseling where parental mosaicism is a concern.

Tertiary prevention. Rehabilitation and falls-prevention to limit complications of progressive motor disability; optimized polytherapy to control myoclonus.

Counseling. Genetic counseling should explain the de novo mechanism, low but non-zero sibling recurrence risk, and the highly penetrant, specific MEAK phenotype.

Section 14 — Other Species / Natural Disease

Taxonomy / orthologs. KCNC1/Kv3.1 is highly conserved across vertebrates. The mouse ortholog is Kcnc1 (NCBI Taxon 10090). Conservation of the S4 voltage sensor and pore underpins the validity of cross-species models.

Natural disease in other species. No well-characterized naturally occurring KCNC1-driven MEAK equivalent is documented in companion animals or wildlife; the disease is defined in humans. (Not applicable / not established in veterinary databases such as OMIA for this specific disorder.)

Comparative biology. Evolutionary conservation of Kv3.1's role in fast-spiking neuron repolarization makes rodent models mechanistically faithful. Zoonotic potential and cross-species transmission are not applicable (genetic, non-infectious disease).

Section 15 — Model Organisms

Mouse models. A 2026 mouse model of the recurrent R320H variant recapitulates the core cellular defect, showing impaired excitability of fast-spiking neurons (PMID: 41705663) — directly modeling the disinhibition mechanism. Constitutive Kcnc1 loss-of-function mice have historically been used to study Kv3.1's role in high-frequency firing, motor coordination, and seizure susceptibility.

In vitro / heterologous models. Heterologous expression (e.g., mammalian cell lines / Xenopus oocytes) with whole-cell patch-clamp is the workhorse for functional classification — demonstrating dominant-negative LoF for R320H (PMID: 25401298), no measurable current with dominant-negative effects for pore variants (PMID: 31353862), gain-of-function for S6 variants (PMID: 36419348), and dominant-positive behavior for p.Thr399Met (PMID: 42347804).

Neuronal / structural models. A neuronal model demonstrated that R320H causes a developmental dendritopathy (PMID: 33735526). Cryo-EM of human Kv3.1 provides a structural model of the gating machinery for drug design (PMID: 35840580).

Computational models. A taxonomy-based multi-task learning SVM predicts gain-/loss-of-function for voltage-gated K+ channel variants, useful for classifying novel KCNC1 variants where experimental data are lacking (PMID: 35759918).

Phenotype recapitulation / limitations. The R320H mouse captures the fast-spiking excitability defect central to MEAK; limitations include incomplete modeling of the full progressive human ataxia/cerebellar-atrophy trajectory and human-specific network effects. In vitro systems capture channel biophysics but not circuit-level disinhibition or progression.

Mechanistic Model / Interpretation

MEAK is best understood as a single-variant channelopathy of fast-spiking neurons with a clean genotype-to-phenotype logic:

    ┌─────────────────────────────────────────┐
    │  KCNC1 c.959G>A (p.Arg320His), de novo   │
    │  S4 voltage sensor · heterozygous        │
    └───────────────────┬─────────────────────┘
                        │ dominant-negative
                        ▼
    ┌─────────────────────────────────────────┐
    │  Kv3.1 heterotetramers lose fast K+      │
    │  current → impaired rapid repolarization │
    └──────────┬───────────────────┬──────────┘
               │                   │
      cortical FS      │                   │   cerebellar
      interneurons     ▼                   ▼   neurons
┌───────────────────────────┐   ┌───────────────────────────┐
│ Disinhibition of cortex   │   │ Cerebellar dysfunction +   │
│ → cortical action         │   │ dendritopathy + cell death │
│   myoclonus + generalized │   │ → ataxia, tremor,          │
│   seizures, giant SEPs    │   │   progressive atrophy      │
└───────────────────────────┘   └───────────────────────────┘
               │                   │
               └─────────┬─────────┘
                         ▼
    ┌─────────────────────────────────────────┐
    │  MEAK: childhood-onset (med 9.5 y),      │
    │  progressive, wheelchair by late teens,  │
    │  transient fever improvement             │
    └─────────────────────────────────────────┘

The fever-improvement phenomenon is the interpretive keystone linking mechanism to therapy: because raising temperature shifts wild-type Kv3.1 activation to more hyperpolarized voltages (increasing channel availability), it partially compensates for the dominant-negative deficit. This is a natural proof-of-concept that pharmacologically augmenting Kv3 channel function could be disease-modifying — the leading rational therapeutic hypothesis, now supported structurally by cryo-EM of the human channel.

The wider KCNC1 allelic series clarifies why MEAK is so stereotyped: the specific biophysical consequence of a variant (dominant-negative LoF vs GoF vs dominant-positive), determined by its structural location (S4 vs pore/S6), maps onto distinct clinical syndromes. This has direct therapeutic implications — Kv3 openers would help LoF/MEAK but could worsen GoF variants — making functional variant classification a prerequisite for precision therapy.

Evidence Base

Concordance. The human cohorts, in vitro electrophysiology, the neuronal dendritopathy study, the mouse model, and the cryo-EM structures converge on a single coherent mechanism (Kv3.1 LoF → fast-spiking neuron dysfunction → disinhibition + cerebellar degeneration). No major contradictions were identified; the GoF and dominant-positive studies refine rather than challenge the model by showing that variant biophysics is context- and location-dependent.

Limitations and Knowledge Gaps

1. Epidemiology is imprecise. No population prevalence/incidence figures exist for MEAK specifically; the 13% figure reflects the fraction of unexplained PME, not general-population frequency.
2. Natural history quantification is limited. Progression rate, long-term survival curves, and validated QoL measures (EQ-5D/SF-36) for MEAK are not established.
3. No disease-modifying therapy validated. Kv3 positive modulation is mechanistically rational but not yet proven in MEAK clinical trials.
4. Modifier genetics unexplored. No modifier genes or epigenetic contributors identified to explain the modest phenotypic variability.
5. Fever effect not therapeutically translated. The temperature-gating link is a compelling clue but its safe therapeutic exploitation (channel openers) requires validation.
6. Model completeness. Existing mouse and in vitro models capture channel biophysics and fast-spiking defects but incompletely recapitulate the progressive human cerebellar-atrophy trajectory.
7. No veterinary/natural-disease counterpart is documented, limiting comparative pathology insight.

Proposed Follow-up Experiments / Actions

1. Preclinical Kv3 opener trials. Test small-molecule Kv3 positive modulators in the R320H mouse model (PMID: 41705663) for rescue of fast-spiking excitability, myoclonus, and ataxia — leveraging the temperature-gating rationale (PMID: 28380698) and cryo-EM structure (PMID: 35840580).
2. Natural-history registry. Establish a prospective MEAK cohort with standardized myoclonus scales, ataxia scores (e.g., SARA), serial MRI cerebellar volumetry, and QoL instruments to quantify progression and define trial endpoints.
3. Biomarker development. Formalize giant SEP amplitude and quantitative EEG/EMG cortical-myoclonus metrics (PMID: 32972906) as objective disease-severity/response biomarkers.
4. Allele-specific therapeutics. Explore allele-selective silencing/ASO strategies against the dominant-negative R320H transcript to relieve poisoning of wild-type Kv3.1.
5. Functional variant pipeline. Apply and extend the ML classifier (PMID: 35759918) plus high-throughput patch-clamp to prospectively classify novel KCNC1 variants (LoF vs GoF), enabling correct therapeutic direction.
6. iPSC-derived interneuron/cerebellar models from patients to study the developmental dendritopathy (PMID: 33735526) and screen candidate compounds in a human genetic background.
7. Genotype-guided prescribing guidance. Codify avoidance of myoclonus-aggravating agents (PMID: 28799509) into KCNC1-specific management pathways to prevent iatrogenic worsening.

Report compiled from 9 confirmed findings across 5 investigation iterations and 19 reviewed papers. Evidence types span human clinical cohorts, in vitro electrophysiology, neuronal and mouse models, structural biology (cryo-EM), and computational prediction.

Artifacts

• OpenScientist final report
• OpenScientist final report